InflaRx Announces Pricing for a Public Offering of Ordinary…
JENA, Germany, April 12, 2023 (GLOBE NEWSWIRE) — InflaRx NV IFRX (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics that target the complement system,